DCDennis Chan

Dennis Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dennis Chan has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cognitive Impairment in Long COVID: PhEnotyping and RehabilitatiOn (CICERO) - COV-LT2-0014

    by Dennis Chan, Aida Suarez-Gonzalez, Martina Vanova, Gina Gilpin, Lottie Ash, Aysha Patel, Zoe Hoare, Nathan Bray, Rachel Evans, Jason Lim

    Plain English Summary Many people experience ongoing difficulties with thinking and memory - often called "brain fog" - after COVID-19 infection, which can significantly affect everyday life. Our research investigated this common and distressing symptom in Long COVID, aiming to understand precisely which mental abilities are affected and test whether a specific therapy could help. Understanding brain fog: We conducted comprehensive assessments on 134 participants experiencing cognitive issues after COVID-19. Participants completed traditional neuropsychological tests and newer, more sensitive digital cognitive assessments measuring attention, memory, and processing speed, alongside questionnaires about their health, mood, sleep, and daily functioning. Our findings provide clear evidence that brain fog is a real, measurable cognitive impairment. We identified a distinct pattern of challenges affecting attention (making it harder to focus), processing speed (leading to slower thinking and reactions), working memory (impacting the ability to hold and use information), and inhibitory control (managing distractions and impulses). Nearly two-thirds of participants showed significant impairment on at least one digital cognitive task. Digital tests proved much more sensitive than traditional assessments, detecting problems that standard tests often missed. We discovered strong connections between cognitive difficulties and other post-COVID symptoms: fatigue, depression, anxiety, and sleep problems were all linked to worse performance. Testing treatment: We then tested whether cognitive rehabilitation therapy - a treatment that helps retrain attention and memory through targeted tasks and practical strategies - could help people with brain fog. Participants received ten weekly therapy sessions via video call, working on personal rehabilitation goals like following conversations, cooking meals, or reading books. People who received the therapy reported it made a real difference, giving them tools to continue doing activities that matter to them. What this means: This research validates patient experiences, provides objective evidence for brain fog, and demonstrates that effective treatment is possible. The strong links between cognitive and other symptoms suggest that comprehensive care addressing multiple issues together may be most effective. Executive Summary Aim: The aim of this study was to determine the nature of the cognitive impairment and deliver cognitive rehabilitation to help a return to normal life. The sheer number of people with Long COVID (LC) makes this a top priority issue for affected individuals and for economies, healthcare and GDP, worldwide. Background: Cognitive impairment is recognised as a major component of LC, present in 25-75% of affected individuals, but little is known about the nature of this impairment, or how it can be treated. The associated loss of functional ability has major consequences for affected people, their families and the wider economy given the problems caused in terms of return to work. Method: The study had two workstreams. The aim of workstream 1 was to establish the phenotype of cognitive impairment in people with LC in whom cognitive decline was their primary LC symptom. To assess this, we adopted a novel test battery, encompassing i) the Repeatable Battery for the Assessment of Neuropsychological State (RBANS), used widely to assess a range of cognitive functions in acquired cognitive disorders such as Alzheimer's disease, ii) a novel set of short digital tests evaluating cognitive speed, attention and executive function, given that these are cognitive domains typically reported to be impaired by people with LC, iii) two specific tests of hippocampal function, in view of concerns at the time of study commencement that the hippocampus may be selectively vulnerable to direct infiltration by the neurotropic SARS-CoV-2 virus via neural pathways from the olfactory bulb. As part of this cross-sectional phenotyping, we also determined how the cognitive impairment in LC was modulated by other aspects of LC, namely fatigue, anxiety/depression and sleep disturbance. Finally, we aimed to identify the imaging correlates of cognitive COVID, using multimodal MRI to measure changes in whole brain and MTL (medial temporal lobe) volume, functional and structural connectivity. Workstream 2 (n=120) represented a randomised controlled trial to determine whether cognitive rehabilitation would help recovery, building on previous work showing that cognitive rehabilitation improves cognitive and functional outcomes in patients with acquired cognitive impairment. The rehabilitation programme focussed on those cognitive domains found in Workstream 1 to be most affected, and included remediation, compensatory and adaptive strategies. The programme was co-produced in collaboration with a group of people living with the disorder, led by a PPI co-investigator. The intervention (cognitive rehabilitation) was compared against standard of care (management of fatigue, anxiety and sleep) for people seen in health services for their condition. Crucially for establishing relevance for real life function, the primary outcome was in the form of participant-set goals (measured using the Bangor Goal Setting Interview) at three months. Secondary outcome measures will be measures of cognition and quality of life at six months. The health economic benefits of treatment were assessed in terms of health resource utilisation, primary (cost per QALY - Quality-Adjusted Life Year) and secondary cost-utility analyses and generation of cost-effectiveness acceptability curves. Patients presenting with cognitive impairment as part of their LC were recruited from the memory clinics at University Hospitals Sussex, University Hospitals Southampton and Greater Manchester Mental Health Trust. Statistical and health economic analyses were undertaken at the Clinical Trials Unit, University of...

  • Open Access

    Clinic evaluation of cognitive impairment in post-COVID syndrome: Performance on legacy pen-and-paper and new digital cognitive tests

    by Aysha Mohamed Rafik Patel, Gina Gilpin, Anna Koniotes, Catherine Warren, Cian Xu, Paul W. Burgess, Dennis Chan


  • Open Access

    Disordered Hippocampal Reactivations Predict Spatial Memory Deficits in a Mouse Model of Alzheimer’s Disease

    by Sarah Shipley, Marco P Abrate, Robin Hayman, Dennis Chan, Caswell Barry

    Alzheimer’s disease (AD) is characterised by progressive memory decline associated with hippocampal degeneration. However, the specific physiological mechanisms underlying hippocampal dysfunction in AD remain poorly understood and improved knowledge may aid both diagnosis and help identify new avenues for therapeutic intervention. We investigated how disruptions in hippocampal reactivations relate to place cell stability and spatial memory deficits in an AD mouse model. Using the APP knock-in mouse model ‘NL-G-F’, we conducted simultaneous behavioural and electrophysiological recordings in a radial arm maze. NL-G-F mice exhibited significant impairments in memory performance, demonstrated by an increased propensity to revisit arms, compared to wild-type controls. These memory deficits were associated with a reduction in the stability of hippocampal place cells, which occurred over short timescales and was accentuated across rest. While the rate of hippocampal reactivation events during rest was unchanged, the structure of these events was significantly degraded in NL-G-F mice. The decreased structure of reactivations was predictive of decreased stability in place cell firing. These findings suggest that disrupted reactivation sequences may act as a mechanism of memory disorder in AD.


  • Open Access

    Telehealth-delivered cognitive rehabilitation for people with cognitive impairment as part of the post-COVID syndrome: protocol for a randomised controlled trial as part of the CICERO (Cognitive Impairment in Long COVID: Phenotyping and Rehabilitation) study

    by Martina Vanova, Aysha Mohamed Rafik Patel, Iona Scott, Gina Gilpin, Emily N. Manning, Charlotte Ash, Philippa Wittenberg, Jason Lim, Zoe Hoare, Rachel Evans, et al.

    Background: Between 25 and 75% of people with persistent post-acute sequelae of SARS-CoV-2 infection (PASC) experience cognitive difficulties, compromising functional ability, quality of life, and activities of daily living, including work. Despite this significant morbidity, there is a paucity of interventions for this disorder that have undergone evaluation within a formal trial setting. Therefore, we have developed a cognitive rehabilitation programme, specifically designed to address the cognitive symptoms of PASC, notably impaired attention and processing speed, while also accounting for other PASC symptoms (fatigue, post-exertional malaise) that may aggravate the cognitive impairment. This study protocol outlines a randomised controlled trial (RCT) designed to evaluate the effectiveness of this programme compared to standard clinical care. Methods: This is a multi-centre, parallel-group, individually randomised controlled trial, comparing standard clinical care with and without cognitive rehabilitation. We will recruit 120 non-hospitalised adults (aged 30–60 years) from three NHS sites in England with a history of COVID-19 infection and cognitive impairment persisting more than 3 months after the acute infection. Participants will be randomised (1:1) to the intervention or control groups, with the latter represented as a provision of standard clinical care without cognitive rehabilitation. The cognitive rehabilitation programme consists of ten 1-hour sessions, delivered weekly. Outcomes will be collected at baseline, 3, and 6 months, with participant-defined goal-attainment scores, relating to functional goals, at 3 months as the primary outcome measure. Secondary outcomes will be cognitive function, measures of quality of life, social functioning, mental health, fatigue, sleep, post-exertional malaise, and social and health care service use. We will also evaluate the health-economic benefits of cognitive rehabilitation in this population. Discussion: Cognitive impairment in PASC is a major cause of functional disability with no effective treatment. Accordingly, we will undertake an RCT of cognitive rehabilitation, the protocol of which is published here. If this trial is successful in delivering improvements in trial outcomes, it will address a major unmet need relating to this emergent disorder, with a significant impact on affected individuals and the wider health economy. Trial registration: ClinicalTrials.gov NCT05731570. Registered on February 16, 2023


  • Open Access

    Telehealth-delivered cognitive rehabilitation for people with cognitive impairment as part of the post-COVID syndrome: Protocol for a randomised controlled trial as part of the CICERO (Cognitive Impairment in Long COVID: Phenotyping and Rehabilitation) study

    by Martina Vanova, Aysha Mohamed Rafik Patel, Iona Scott, Gina Gilpin, Emily N Manning, Charlotte Ash, Philippa Wittenberg, Jason Lim, Zoe Hoare, Rachel Evans, et al.

    Background Between 25–75% of people with persistent post-acute sequelae of SARS-CoV-2 infection (PASC) experience cognitive difficulties, compromising functional ability, quality of life, and activities of daily living, including work. However, despite this significant morbidity, there is a paucity of interventions for this disorder that have undergone evaluation within a formal trial setting. Therefore, we have developed a cognitive rehabilitation programme, specifically designed to address the cognitive symptoms of PASC, notably impaired attention and processing speed, while also accounting for other PASC symptoms (fatigue, post-exertional malaise) that may aggravate the cognitive impairment. This study protocol outlines a randomised controlled trial (RCT) designed to evaluate the effectiveness of this programme compared to standard clinical care. Methods This is a multi-centre, parallel-group, individually randomised control trial, comparing standard clinical care with and without cognitive rehabilitation. We will recruit 120 non-hospitalised adults (aged 30–60 years) from three NHS sites in England with a history of COVID-19 infection and cognitive impairment persisting more than three months after the acute infection. Participants will be randomised (1:1) to the intervention or control groups, with the latter represented as a provision of standard clinical care without cognitive rehabilitation. The cognitive rehabilitation programme consists of ten one-hour sessions, delivered weekly. Outcomes will be collected at baseline, three and six months, with participant-defined goal-attainment scores, relating to functional goals, at three months as the primary outcome measure. Secondary outcomes will be cognitive function, measures of quality of life, social functioning, mental health, fatigue, sleep, post-exertional malaise, and social and health care service use. We will also evaluate the health-economic benefits of cognitive rehabilitation in this population. Discussion Cognitive impairment in PASC is a major cause of functional disability with no effective treatment. Accordingly, we will undertake an RCT of cognitive rehabilitation, the protocol of which is published here. If this trial is successful in delivering improvements in trial outcomes, it will address a major unmet need relating to this emergent disorder, with a significant impact on affected individuals and the wider health economy. Trial registration NCT05731570.

  • Open Access

    Early detection of diseases causing dementia using digital navigation and gait measures: A systematic review of evidence

    by Giedrė Čepukaitytė, Coco Newton, Dennis Chan

    Wearable digital technologies capable of measuring everyday behaviors could improve the early detection of dementia‐causing diseases. We conducted two systematic reviews following Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) guidelines to establish the evidence base for measuring navigation and gait, two everyday behaviors affected early in AD and non‐AD disorders and not adequately measured in current practice. PubMed and Web of Science databases were searched for studies on asymptomatic and early‐stage symptomatic individuals at risk of dementia, with the Newcastle–Ottawa Scale used to assess bias and evaluate methodological quality. Of 316 navigation and 2086 gait records identified, 27 and 83, respectively, were included in the final sample. We highlight several measures that may identify at‐risk individuals, whose quantifiability with different devices mitigates the risk of future technological obsolescence. Beyond navigation and gait, this review also provides the framework for evaluating the evidence base for future digital measures of behaviors considered for early disease detection.


  • Open Access

    Entorhinal‐based path integration selectively predicts midlife risk of Alzheimer's disease

    by Coco Newton, Marianna Pope, Catarina Rua, Richard Henson, Zilong Ji, Neil Burgess, Christopher T. Rodgers, Matthias Stangl, Maria‐Eleni Dounavi, Andrea Castegnaro, et al.

    INTRODUCTION: Entorhinal cortex (EC) is the first cortical region to exhibit neurodegeneration in Alzheimer's disease (AD), associated with EC grid cell dysfunction. Given the role of grid cells in path integration (PI)–based spatial behaviors, we predicted that PI impairment would represent the first behavioral change in adults at risk of AD.METHODS: We compared immersive virtual reality (VR) PI ability to other cognitive domains in 100 asymptomatic midlife adults stratified by hereditary and physiological AD risk factors. In some participants, behavioral data were compared to 7T magnetic resonance imaging (MRI) measures of brain structure and function.RESULTS: Midlife PI impairments predicted both hereditary and physiological AD risk, with no corresponding multi‐risk impairment in episodic memory or other spatial behaviors. Impairments associated with altered functional MRI signal in the posterior‐medial EC.DISCUSSION: Altered PI may represent the transition point from at‐risk state to disease manifestation in AD, prior to impairment in other cognitive domains.


  • Open Access

    Path integration selectively predicts midlife risk of Alzheimer’s disease

    by Coco Newton, Marianna Pope, Catarina Rua, Richard Henson, Zilong Ji, Neil Burgess, Christopher T. Rodgers, Matthias Stangl, Maria-Eleni Dounavi, Andrea Castegnaro, et al.

    The entorhinal cortex (EC) is the first cortical region to exhibit neurodegeneration in Alzheimer’s disease (AD), associated with EC grid cell dysfunction. Given the role of grid cells in path integration, we predicted that path integration impairment would represent the first behavioural change in adults at-risk of AD. Using immersive virtual reality, we found that midlife path integration impairments predicted both hereditary and physiological AD risk, with no corresponding impairment on tests of episodic memory or other spatial behaviours. Impairments related to poorer angular estimation and were associated with hexadirectional grid-like fMRI signal in the posterior-medial EC. These results indicate that altered path integration may represent the transition point from at-risk state to disease onset in AD, prior to impairment in other cognitive domains.


  • Open Access

    Mild Cognitive Impairment: the Manchester consensus

    by Ross A Dunne, Dag Aarsland, John T O’bRien, Clive Ballard, Sube Banerjee, Nick C Fox, Jeremy D Isaacs, Benjamin R Underwood, Richard J Perry, Dennis Chan, et al.

    Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15% of people developing dementia per year. However, ~50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer’s disease to be made where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI.